Two Major Psychedelics Companies Bring Novel Chemical Entity Patent Battle to Federal Court – Reunion Neuroscience (NASDAQ: REUN), Mindset Pharma (OTC: MSSTF)

Clinical-stage biopharma company Reunion Neuroscience Inc. reune Lawsuit filed against drug discovery business Mindset Pharma Inc. msstaff In the District Court of New Jersey. Reunion alleges that Mindset intentionally copied its psychedelic compound RE104 – a Novel Chemical Entity (NCE) – and presented it as novel to the USPTO when applying for IP coverage.

See also: Psychedelics companies explore and protect their discoveries, this firm is doing in 16 countries

reunion Target to nominate the company’s CSO, the original and sole inventor of its compound RE104 Dr. Nathan Brysonas an inventor of Mindset’s patent application as well as co-ownership over it, as well as claims of disparate conduct in patent prosecution and breach of contract.

Mindset has responded that it “disagrees with and denies the allegations made by Reunion,” and that it plans to vigorously defend itself against the suit.

Patent case of RE104

USPTO Awarded Reunion Patent covers RE104 -then called FT104-, a 4-OH-DiPT prodrug and novel psychedelic compound, for Postpartum Depression (PPD) Treatment and other mental health conditions in April 2022.

See also: Reunion Neuroscience claims ‘transformational’ trimester, postpartum depression treatment confirmed

The patent grant also made the drug’s composition public, giving the company exclusive production and sales rights until 2041.

In the lawsuit, Reunion said that Mindset copied it and submitted the creation in June 2022 to the same federal entity as its invention. The company said the issue affects its third-party funding.

Reunion is now claiming in court: an improvement of the invention in Mindset’s patent, including the USPTO director to issue a corresponding certificate of improvement; a declaration stating that it co-owns Mindset’s patents and inventions; a statement on the engagement of the Mindset in the conduct which in effect voids the patent; and financial compensation for attorney expenses and benefit damages.

second edition of Benzinga Psychedelics Capital Conference Getting closer every day!

Taking place on April 13, 2023 at the Fontainebleau Miami Beach Hotel in Florida, the event is the place to get deals done, raise money, jumpstart M&A, and meet investors and key partners.

GET YOUR TICKETS NOW Before the prices go up!

Photo: Benzinga edit with photos by flamemetric, ayoshi597, Giselle Yasher, baxika, and freedomz on Shutterstock.

Source link

Leave a Comment